...
首页> 外文期刊>Brazilian Dental Journal >Osteonecrosis Related to Once-Yearly Zoledronic Acid Treatment in an Osteoporotic Patient after Dental Implant
【24h】

Osteonecrosis Related to Once-Yearly Zoledronic Acid Treatment in an Osteoporotic Patient after Dental Implant

机译:牙种植后骨质疏松患者每年一次唑来膦酸治疗相关的骨坏死

获取原文
           

摘要

This paper presents a case of osteonecrosis of the jaw related to zoledronic acid (5 mg) administered once yearly to treat osteoporosis. A 79-year-old woman who has been treated for osteoporosis for 5 years with 5 applications of zoledronic acid was referred for evaluation. The patient had been submitted to dental implant placement and there was no osseointegration. On clinical examination, suppuration and exposed bone on the alveolar ridge were observed. Radiographic examination revealed an osteolytic area and bone sequestration. Both clinical and radiological features were suggestive of osteonecrosis. The treatment consisted of surgery to remove the affected bone completely. The patient is asymptomatic at 9 months after surgery. Dentists and oral surgeons should be alert to the possibility of osteonecrosis related to the use of once-yearly injections of zoledronic acid for the treatment of postmenopausal osteoporosis.
机译:本文介绍了与唑来膦酸(5 mg)相关的下颌骨坏死病例,每年服用一次以治疗骨质疏松症。一位79岁的女性接受了5次唑来膦酸的骨质疏松症治疗,治疗5年。该患者已经接受了种植牙的植入,没有骨整合。在临床检查中,观察到化脓和牙槽骨暴露。影像学检查发现溶骨区和骨固着。临床和放射学特征均提示骨坏死。治疗包括手术以完全去除患骨。术后9个月该患者无症状。牙医和口腔外科医师应警惕可能每年使用一次唑来膦酸注射液治疗绝经后骨质疏松症所致的骨坏死的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号